Lycia Therapeutics, Inc. (NASDAQ:LYCA – Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 15,000 shares of the company’s stock in a transaction on Wednesday, October 28th. The stock was bought at an average cost of $25.45 per share, for a total transaction of $381,750.00. Following the acquisition, the insider directly owned 6,840,233 shares of the company’s stock, valued at $174,083,929.85. This represents a 0.22% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Friday, October 30th, Venrock Healthcare Capital Par acquired 9,004 shares of Lycia Therapeutics stock. The shares were bought at an average price of $26.28 per share, with a total value of $236,625.12.
- On Thursday, October 29th, Venrock Healthcare Capital Par acquired 1,000 shares of Lycia Therapeutics stock. The shares were bought at an average price of $26.33 per share, with a total value of $26,330.00.
- On Tuesday, October 27th, Venrock Healthcare Capital Par acquired 39,796 shares of Lycia Therapeutics stock. The shares were bought at an average cost of $26.62 per share, with a total value of $1,059,369.52.
- On Monday, October 26th, Venrock Healthcare Capital Par acquired 1,952,705 shares of Lycia Therapeutics stock. The shares were bought at an average cost of $18.04 per share, with a total value of $35,226,798.20.
- On Friday, October 23rd, Venrock Healthcare Capital Par bought 52,939 shares of Lycia Therapeutics stock. The stock was bought at an average price of $25.91 per share, for a total transaction of $1,371,649.49.
Lycia Therapeutics Stock Down 4.8%
Shares of NASDAQ LYCA opened at $26.40 on Friday. Lycia Therapeutics, Inc. has a 52-week low of $22.19 and a 52-week high of $36.49.
Lycia Therapeutics Company Profile
Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.
Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.
Featured Articles
- Five stocks we like better than Lycia Therapeutics
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
